1st Counsel – Lifestyle
Author:
Editas Medicine, Inc.
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
April 27, 2026
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
March 27, 2026
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
March 9, 2026